Clinical trials: Chemotherapy-related Cognitive Dysfunction
Chemotherapy-Related Cognitive Impairment
Electroacupuncture for Chemotherapy-Related Cognitive Impairment
The objective of this trial is to evaluate the effect of electroacupuncture compared to sham acupuncture in preventing CRCI among breast cancer patients scheduled to undergo chemotherapy.
- Trial name
- NCT05941598
- Testing
- Electroacupuncture
- Volunteers
- 100 people
- Sponsor
- Beijing University of Chinese Medicine
Breast Cancer, Neurotoxicity
EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer
RATIONALE: Chemotherapy may cause memory loss, attention loss, and other problems that make it difficult for patients to think clearly. EGb761 may help maintain mental clarity in patients undergoing chemotherapy.
- Trial name
- NCT00046891
- Testing
- Ginkgo Biloba
- Where
- 175 sites in United States
- Volunteers
- 226 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Oncology, Cancer-related Cognitive Impairment
Effects of Cognitive Training on Chemotherapy-Induced Cognitive Impairment in Colon Cancer Patients Undergoing Treatment(Chemobrain) in Oncology Patients With Colon Cancer Undergoing Active Treatment
Introduction: With the increasing survival rate in colon cancer, as a result of technological and biomedical advancements, it is essential to thoroughly study the secondary symptoms related to the oncological disease process.
- Conditions
- Oncology, Cancer-related Cognitive Impairment, Cognitive Training, Everyday Cognition
- Trial name
- NCT06710639
- Testing
- Health Education Program, Cognitive Training Program
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Salamanca
Breast Cancer
Evaluation of Cognitive Management for Chemobrain in Patients Treated for Breast Cancer.
This project will investigate the efficacy of a cognitive remediation programme in patients treated for breast cancer. patients will be randomized between "no intervention" and "intervention programme".
- Trial name
- e-ONCOGITE (NCT05690828)
- Testing
- Cognitive remediation
- Where
- France
- Volunteers
- 164 people
- Sponsor
- Institut Bergonié
Breast Cancer, Non-Hodgkin's Lymphoma
Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release
The purpose of this study is to determine whether the drug mesna is able to block a series of chemical changes that occur in the blood of patients who receive the chemotherapy medicine doxorubicin.
- Trial name
- NCT01205503
- Testing
- Mesna, Saline, Doxorubicin
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Mara Chambers
Breast Neoplasms, Exercise Therapy
Aerobic Dance During Chemotherapy in Breast Cancer Patients With Cognitive Impairment
The goal of this clinical trial is to learn about breast cancer patients. The main questions it aims to answer are: Does Aerobic Dance During Chemotherapy Improve Cognitive Function in Breast Cancer Patients？ Does the efficacy of…
- Conditions
- Breast Neoplasms, Exercise Therapy, Chemotherapy-Related Cognitive Impairment, Cognitive Dysfunction
- Trial name
- ADANC (NCT06234150)
- Testing
- Aerobic dance, Fast-walking
- Where
- China
- Volunteers
- 90 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Diffuse Large B-Cell Lymphoma
Cognitive Impairment in Patients With Diffuse Large B-Cell Lymphoma
This prospective, non-randomized diagnostic interventional study evaluates cognitive impairment in patients with diffuse large B-cell lymphoma (DLBCL) treated at the Institute of Oncology Ljubljana.
- Trial name
- NCT07443514
- Testing
- Structured Neurocognitive Assessment Battery, Psychometric Questionnaires, CSF Biomarker Analysis
- Where
- Slovenia
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Institute of Oncology Ljubljana
Cognitive Impairment
Cancer Related Cognitive Impairment After Chemotherapy: Evaluation of Potential Therapeutic Interventions
Background: Mindfulness has been applied to improve after cancer care by enhancing psychological well-being; however, little is known about its impact on cognitive impairment experienced by cancer patients after chemotherapy.
- Trial name
- NCT03736460
- Testing
- Mindfulness, Physical training
- Where
- Belgium
- Volunteers
- 120 people
- Sponsor
- KU Leuven
Cognitive Impairment, Chemobrain
Cognitive Impairment in Treated Breast Cancer Survivors: Possible Approaches
The investigators aim is to conduct a prospective study with three arms, involving non-metastatic breast cancer patients who underwent chemotherapy as part of their treatment and were on a form of hormone therapy at the time of…
- Trial name
- NCT06662474
- Testing
- 1. cognitive stimulation, 2. psychoeducation and cognitive stimulation, 3. no intervention
- Volunteers
- 120 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Breast Neoplasms
Telehealth Program to Prevent Cancer and Chemotherapy-related Cognitive Impairment.
The present randomized controlled trial has the main objective to study the effects of a videoconferenced occupational therapy program in preventing cancer and chemotherapy-related cognitive impairment and other health outcomes…
- Trial name
- NCT04783402
- Testing
- e-OTCAT program, Educational handbook and standard care
- Where
- Spain
- Volunteers
- 98 people
- Sponsor
- Universidad de Granada
Oncology, Support Care
Breast Cancer and Chemobrain : Effects of Photobiomodulation on the Improvement of Perceived Cognitive Impairment
Breast cancer is one of the most common cancers in metropolitan France, with over 60,000 new cases in 2023. Mostly a female cancer, it can affect a young population, with around 20% of breast cancers occurring in women under 50.
- Conditions
- Oncology, Support Care, Cognitive Disorders
- Trial name
- REGAIN (NCT06995443)
- Testing
- Photobiomodulation
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier de Valenciennes
Cancer, Sarcopenia
JUMP Prevalence of Sarcopenia and Chemobrain in Post-cancer Patients
Therapeutic advances in oncology have transformed the prognosis of cancer patients, placing a significant number of them either in a context of recovery or in prolonged remission close to a chronic disease.
- Trial name
- JUMP (NCT05800535)
- Testing
- Study of the adverse effects of long-term oncological treatments, Study of the long-term side effects of oncological treatments on the anxiety-depressive and cognitive state of patients
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Breast Cancer
CHEmotherapy and Cognitive Deterioration in Patients With Operable Breast Cancer: Impact of Cognitive Rehabilitation (CHEMOFOG)
An interventional, non-pharmacological, monocentric study evaluating the effectiveness of cognitive rehabilitation in counteracting chemotherapy-induced cognitive impairment (CRCI) in women with operable breast cancer treated…
- Trial name
- CHEMOFOG (NCT06435559)
- Testing
- Neurotablet® and Neuropsychological evaluations, Neuropsychological evaluations
- Volunteers
- 128 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Cognitive Disorders, HIV Infections
A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia
The purpose of this study is to see if it is safe and effective to give thioctic acid and deprenyl (selegiline hydrochloride), alone or in combination, to HIV-infected patients who have mild to moderate dementia (a decline in…
- Trial name
- NCT00002154
- Testing
- Thioctic acid, Selegiline hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- The Dana Foundation
Chemotherapy-Related Cognitive Impairment, DL-3-n-butylphthalide
Effects of DL-3-n-butylphthalide on Chemotherapy-Induced Cognitive Impairment
Chemotherapy-related cognitive Impairment (CICI) is a series of neurocognitive deficits experienced during and after cancer chemotherapy.
- Trial name
- NCT06508671
- Testing
- DL-3-n-butylphthalide, Empty Medication Capsules
- Volunteers
- 100 people
- Sponsor
- First Hospital of China Medical University
Survivors of Childhood Cancer
Technological Gaming in Cancer Survivors (WINNERS)
HYPOTHESIS 1. Neurocognitive deficits in cancer survivors are underestimated. They represent a very limiting long-term side effect in this group of patients. 2.
- Trial name
- WINNERS (NCT06312969)
- Testing
- Video game based training
- Where
- Spain
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Antonio Pérez Martínez
Breast Cancer, Cognitive Symptoms
Computer-Based Training in Patients With Post-Chemotherapy Cognitive Impairment
The investigators hypothesize that continuous active interaction with environments that are demanding to sensory, cognitive, and motor systems, together with imbedded rewards for successful performance, will help improve memory…
- Conditions
- Breast Cancer, Cognitive Symptoms, Memory Disorders
- Trial name
- NCT00387062
- Testing
- Computer-based Cognitive Training
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Posit Science Corporation
Chemotherapy-Related Cognitive Impairment
Biomarkers for Chemotherapy Associated Neurotoxicity
To assess if biomarkers can be used to predict early treatment related neurotoxicity in patients with Acute lymphoblastic leukaemia (ALL) or lymphoblastic lymphoma (LBL) and to inform development of novel interventions.
- Trial name
- BioCAN (NCT05280262)
- Testing
- CogState Test
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- NHS Greater Glasgow and Clyde
Chemotherapy-Related Cognitive Impairment, Breast Cancer
GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer
The purpose of this study is to evaluate the prophylactic effects of Ganglioside-Monosialic Acid in post-chemotherapy cognitive impairment in patients with early operable breast cancer.
- Trial name
- NCT05239663
- Testing
- Ganglioside-Monosialic Acid, 250ml normal saline (NS)
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Sun Yat-sen University
Cancer-related Problem/Condition, Cognitive Impairment
Memory and Attention Adaptation Training-Geriatrics (MAAT-G) Phase II
Cancer-related cognitive dysfunction (CRCD) affects up to 75% of patients receiving chemotherapy and older adults are at greater risk of developing CRCD, which can negatively affect their functional independence and quality of…
- Trial name
- NCT04669301
- Testing
- MAAT-G, Supportive therapy (time and attention control)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Rochester